跳至主要内容
临床试验/TCTR20221014007
TCTR20221014007已完成2 期

Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia

ocal, in Arifin Achmad Hospital0 个研究点目标入组 60 人开始时间: 2022年10月14日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 Years 至 40 Years(—)
性别
Female

入选标准

  • All pregnant women with a diagnosis of severe preeclampsia. Gestational age of 28 to 34 weeks. Live fetus. Upper arm circumference 23.5 to 33 cm. Willing to participate in research. Hemoglobin level 10.5 g/dl.

排除标准

  • 1. Pregnant women with severe preeclampsia with decreased consciousness. 2. Pregnant women with severe preeclampsia accompanied by complications/complications such as eclampsia, HELLP syndrome, kidney failure, or acute pulmonary oedema. 3. Pregnant women with severe preeclampsia in labor. 4. Pregnant women with severe preeclampsia who received antihypertensive therapy in the last 12 hours. 5. Pregnant women with severe preeclampsia who have a history of allergy to the trial drug. 6. Pregnant women with severe preeclampsia who have a history of asthma and heart disease.

研究者

发起方
ocal, in Arifin Achmad Hospital

相似试验

Effectiveness of nifedipine, labetalol, and... | 临床试验